Nomic, founded in 2017 by bioengineers at McGill University, is a life sciences technology company that develops platforms for large-scale, quantitative protein profiling. Its core technology, the nELISA platform, applies principles from DNA nanotechnology, high-dimensional flow cytometry, and lab automation to enable high-throughput proteomics. The company's stated mission is to make biology easier to measure, thereby democratizing access to proteomic data.
The company's commercial offering includes the Omni 1000 platform, which provides quantitative analysis of 1,000 proteins at a cost of $50 per sample. This technology supports work in drug discovery and biomarker identification for clients including six of the top ten global pharmaceutical companies and over 100 institutions worldwide. Nomic operates at significant scale, having profiled over 523,000 samples and 121 million proteins, with a facility capable of processing 2.5 million samples and generating 500 million protein assays annually.
Nomic has raised $59 million in total funding through a Series B round. The company's technical work integrates machine learning with its core nanotechnology and automation domains to support its analytical platforms.
